Scottish Medicines Consortium Accepts RINVOQ®▼(u

MAIDENHEAD, UK, 10 OCTOBER 2022: AbbVie (NYSE: ABBV) today announced that the Scottish Medicines Consortium (SMC) has accepted RINVOQ® (upadacitinib) for use within NHS Scotland* for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lo...

Related Keywords

United Kingdom , Glasgow , Glasgow City , Scotland , Jonathan Macdonald , Belinda Byrne , Ruth Wakeman , National Institute Of Diabetes , Scottish Medicines Consortium , Consultant Gastroenterologist , Marketing Authorisation , Colitis United , Medical Director , Abbvie United , Patient Access Scheme , Maintenance Therapy , Subjects With Moderately , Severely Active Ulcerative , Participants With Moderately , Severely Active Ulcerative Colitis ,